Evidence map›Paper›PMID 27890933›Full record

ArticleLeukemia2017

Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.

K T Siu, J Ramachandran, A J Yee, H Eda, L Santo, C Panaroni, J A Mertz, R J Sims Iii, M R Cooper, N Raje

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Novel targeted therapies in chronic myeloid leukemia.Pharmaceutical science advances · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. BET Proteins as Attractive Targets for Cancer Therapeutics.International journal of molecular sciences · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

K T SiuMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
J RamachandranMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
A J YeeMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
H EdaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
L SantoMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
C PanaroniMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
J A MertzConstellation Pharmaceuticals, Inc., Cambridge, MA, USA.
R J Sims IiiConstellation Pharmaceuticals, Inc., Cambridge, MA, USA.
M R CooperConstellation Pharmaceuticals, Inc., Cambridge, MA, USA.
N RajeMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Harvard University · USConstellation Pharmaceuticals (United States) · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of the bromodomain and extra-terminal (BET) proteins is a promising therapeutic strategy for various hematologic cancers. Previous studies suggest that BET inhibitors constrain tumor cell proliferation and survival mainly through the suppression of MYC transcription and activity. However, suppression of the transcription of additional genes also contributes to the antitumor activity of BET inhibitors but is less well understood. Here we examined the therapeutic potential of CPI-0610, a potent BET inhibitor currently undergoing phase I clinical testing, in multiple myeloma (MM). CPI-0610 displays potent cytotoxicity against MM cell lines and patient-derived MM cells through G

Indexed as

AnimalsBenzazepinesBromodomain Containing ProteinsCell Cycle ProteinsG1 Phase Cell Cycle CheckpointsHumansIkaros Transcription FactorInterferon Regulatory Factor-4Interferon Regulatory FactorsIsoxazolesMiceMultiple MyelomaNuclear ProteinsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-mycTranscription FactorsBenzazepinesBRD2 protein, humanBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsCPI-0610Ikaros Transcription FactorIKZF1 protein, humanInterferon Regulatory Factor-4Interferon Regulatory FactorsIsoxazolesMYC protein, humanNuclear ProteinsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-mycTranscription Factors

Identifiers

PMID27890933
OpenAlexW2557763600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.